Eltrombopag (ATC: B02BX05), an orphan drug authorized for marketing by EMA in 2010, is an oral thrombopoietin receptor agonist indicated for adult patients with acquired aplastic anemia (SAA). This evidence concerns the gene MPL and severe aplastic anemia.